ID   OV-MZ-9
AC   CVCL_X964
SY   OVMZ-9
DR   Wikidata; Q54936872
RX   DOI=10.5282/edoc.3898;
RX   PubMed=11242531;
RX   PubMed=15706405;
CC   Omics: Transcriptomics; Microarray.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C7978; Ovarian serous cystadenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 05-09-14; Last updated: 10-04-25; Version: 7
//
RX   DOI=10.5282/edoc.3898;
RA   Euer N.I.;
RT   "Identification of target genes for the therapy and diagnosis of
RT   ovarian carcinoma.";
RL   Thesis PhD (2005); Ludwig Maximilians University of Munich; Munich; Germany.
//
RX   PubMed=11242531; DOI=10.1089/10430340150504019;
RA   Bruning A., Kohler T., Quist S.R., Wang-Gohrke S., Mobus V.J.,
RA   Kreienberg R., Runnebaum I.B.;
RT   "Adenoviral transduction efficiency of ovarian cancer cells can be
RT   limited by loss of integrin beta3 subunit expression and increased by
RT   reconstitution of integrin alphaVbeta3.";
RL   Hum. Gene Ther. 12:391-399(2001).
//
RX   PubMed=15706405; DOI=10.3892/or.13.3.375;
RA   Euer N.I., Kaul S., Deissler H., Mobus V.J., Zeillinger R.,
RA   Weidle U.H.;
RT   "Identification of L1CAM, Jagged2 and neuromedin U as ovarian
RT   cancer-associated antigens.";
RL   Oncol. Rep. 13:375-387(2005).
//